HVTN 302 immunogenicity + safety manuscript (Science Translational Medicine)doi:10.7910/DVN/Y8OC5LHarvard Dataverse2025-07-152HIV Vaccine Trial Network Statistics and Data Management Center, 2025, "HVTN 302 immunogenicity + safety manuscript (Science Translational Medicine)", https://doi.org/10.7910/DVN/Y8OC5L, Harvard Dataverse, V2, UNF:6:6H6owm5SNRC+IOkOi1BXSw== [fileUNF]HVTN 302 immunogenicity + safety manuscript (Science Translational Medicine)Membrane-anchored HIV Env trimer mRNA vaccine elicits tier 2 neutralizing antibodies in humansdoi:10.7910/DVN/Y8OC5LHIV Vaccine Trial Network Statistics and Data Management CenterHarvard DataverseHIV Vaccine Trials Network Statistics and Data Management CenterHVTN SDMC2025-04-22Medicine, Health and Life SciencesHIV-1Clinical trial, phase 1HumansHIV vaccinesmRNA vaccinesHIV Vaccines* / immunologyThis dataset is in support of a pending publication in Science Translational Medicine. A full citation will be added when the manuscript is published.<a href="http://creativecommons.org/licenses/by-nc-nd/4.0">CC BY-NC-ND 4.0</a>reacto_list.tab2612512text/tab-separated-valuesUNF:6:Yx1ur42+3YrLicgNZ+sjxQ==This dataset contains interim locked data as of 23 November 2023.v302_bama.tab7334415text/tab-separated-valuesUNF:6:eaHFCtCsjvHNyMlnTZOoZQ==This dataset contains locked data as of 22 January 2025.v302_bcp.tab884912text/tab-separated-valuesUNF:6:H3tuOFh2+lvtNZVZPtzH5Q==This dataset contains frozen data as of 24 January 2024.v302_empem.tab68714text/tab-separated-valuesUNF:6:a//3DTswRnbNr8KP4ubrOQ==This dataset contains frozen data as of 10 October 2024.v302_ics.tab462114text/tab-separated-valuesUNF:6:Opid9ZqX9feX0FjIUiWrIw==This dataset contains locked data as of 22 January 2025.v302_nab_mabs.tab47415text/tab-separated-valuesUNF:6:3rWVz1qREdyiJn+fnxQlYw==This dataset contains frozen data as of 3 September 2024.v302_nab.tab224414text/tab-separated-valuesUNF:6:oRJy1tZKwYE/KGiFCKHZ5Q==This dataset contains locked data as of 4 September 2024.UID.9.026125.0953.0418.477856459205373.0268.28780909436130.0UNF:6:qkbm7S82YfCrzBASBxq9Vg==VISIT0.010.06.05.69102392344498.2.03.271993092311076326125.0UNF:6:4yRM8GbwvYTAdjW088+M/A==RGBASEFLAG0.00.00.0.0.00.026125.00.0UNF:6:27DQnHtvR0B0Jl4Kormyvw==RGTYPEUNF:6:q4HnMquP8mYnkW4+dHXTFw==RGPARAMUNF:6:FCHIhc43HHmvt7znKWd0Aw==RGPARAMCUNF:6:/PnyzdNRiVcrZ450BrEW2Q==RGLOCUNF:6:Lsjkq0tL2Z0vfSIpBBH9Qg==RGEVAL1.010.0.2.586419815963419726125.05.00.04.9946794258373215UNF:6:wRqzRzKfS7b+MI3YVb6dyA==RGEVALCUNF:6:3GB2HlzxghOq+E0hMSQ3xg==RGDGRADE0.38333844294943760.00.026125.0.0.114602870813395260.03.0UNF:6:50WBLwcpHMZMKP7oYkvdeQ==RGDGRADE_TXTUNF:6:6cvnmtL+M1zfFPijfK75/Q==VACN1.0.0.81799827307776912.01.9227559808612453.026125.00.0UNF:6:200r63rxGMnW86LC3IUj0Q==NETWORKUNF:6:OjYpKSRtvDm5BSqqMR0wig==PROTOCOL302.0.302.00.073344.0302.00.0302.0UNF:6:ZtypQvlVJgSIjlsh0yL52A==ASSAYUNF:6:8YTqa7oSUCBPZOQjqyMAYw==UID9.0264.8960256498752473344.0370.0415.4079679320671953.0.0.0UNF:6:4QtTI7pJ2/n9Fb8t//qPKA==RX_CODEUNF:6:1uei5v7MYqz6aRKmnR9sfQ==RX_LABELUNF:6:dRQePZDnZzAzsPPfyxESNw==VISITNO4.7175107084003742.015.08.0.7.81871727748688450.073344.0UNF:6:q14zgJZN1A3v64W1fkkz3w==MONTHUNF:6:q6Bhg72WmsSd4zpNTUpTtw==ISOTYPEUNF:6:hMBabFwuTMRgUXbfSB31qw==ANALYTEUNF:6:ZkslAHLTBRFAgjnX4UleXA==DILUTION156250.050.056383.449211343632550.03750.00.073344.0.UNF:6:uocWdDRU36THSHN5OLMspg==DELTA897.37891647578971.0.3556.96441400625240.022000.03.573344.0UNF:6:y4RLEENFguMZ8vDAvx9zGA==DELTA_UNITUNF:6:iDW9jShy1YhbGTkKHYGpvg==RESPONSE0.00.451497918678291870.2851671669599433.1.057966.015378.00.0UNF:6:IvKx2A0K3unNG/9u9dUBIQ==AUC2914.77804448905950.08254.84254707452588.093.88040870738152.72756.070311.31490367206UNF:6:X26DBXXMKObjQWG1gMXGdw==NETWORKUNF:6:21nXzEgxHTjyRRbN9nQFBQ==PROTOCOL302.0302.00.00.0302.0302.08849.0.UNF:6:7pdrbAtBrKaL6eq8dTUYRw==ASSAYUNF:6:oJ0hg9r/ZyIcxUuwBaoBYQ==UID953.08849.0366.09.0.0.0260.83430239896455409.1411458921772UNF:6:4y//nx0i0GoKIKV5zMpf2w==RX_CODEUNF:6:by294AzBSjaaGeJM6Z0DKw==RX_LABELUNF:6:prUUGgoAFSDu68ZMqgMsuA==VISITNO4.7025064099206390.015.08849.0.9.5993897615549762.012.0UNF:6:9y+NrIfg2I5r/L6WpHpCUw==MONTHUNF:6:3f4Nm8/4qj+8uvWelXr7Zw==LABELUNF:6:5DenpxYVZjVzRobpiPMmiw==MAGNITUDE.100.08845.00.0822030415125364.09.5324440617372410.020.29318682858654UNF:6:b/tP31jyHVqhB3/v9/Dobg==RESPONSE0.284676503972758439.08810.00.01.00.45128583940483160.0.UNF:6:oE1E3OmOFWTfa3E6+BBiGw==REASONUNF:6:LJ1OQmYaPAtubRG1ikEDHw==NETWORKUNF:6:mjfQ5WBGxSkFCu17BOyOQw==PROTOCOL687.0302.0302.0302.0302.00.0.0.0UNF:6:UyBC4wm3piEbCGYDXUZYZA==ASSAYUNF:6:+Kxp6vtwqxbZQjtsoOnzsQ==UID456.96506550218359.0461.0687.0268.0222543128762.953.00.0UNF:6:PIpF/IIGOApNEarCUSp55w==RX_CODEUNF:6:Hw+IMKdD1m11wL8pOewp6Q==RX_LABELUNF:6:NiD0zD0fxd5kbDbHBQ0SBA==VISITNO0.08.012.01.130131449074325311.65065502183406687.012.0.UNF:6:vuZ0WltzwsTOW017rOJcww==MONTHUNF:6:pX6At4+1Hlp+ZdCdfmx9Cw==ISOTYPEUNF:6:jS5nXkPXhYkW3/B0mvq5cg==ANTIGENUNF:6:D3yo+seNAtVsRFiM0lFWEA==EPITOPEUNF:6:wKoJ5jqSCDfaCJyaq7vkPw==MAGNITUDE5.0622.00.67932508484338520.00.065.0.0.23643086816720219UNF:6:/eHz5pwIv3PgJ4nzKWgcYQ==RESPONSE0.00.00.247452692867539881.00.43184640229900717687.0.0.0UNF:6:8PsLTso4qjBOHWvF6xc10A==TOTAL_MAGNITUDE0.54740101939260982.78000000000000020.0.138.0549.00.49278688524590150.39UNF:6:sntDy15jDqrch4UW4BDkow==NETWORKUNF:6:JJxSSz45X4KbD6C9q6vS+A==PROTOCOL.302.00.0302.0302.04621.00.0302.0UNF:6:JrLgnjffVZoZzNsA0wnmSg==ASSAYUNF:6:GkwtTzS9tKFtEx62WO98pA==UID9.0261.0961663298139370.0.0.0953.04621.0414.45358147585847UNF:6:bUhQN0Jej8F/KFS5gtHMfA==RX_CODEUNF:6:vqWQalxmB5kyx201vOdOnQ==RX_LABELUNF:6:r6pmJMnM/pwgcMiZiokmJQ==VISITNO.12.05.5114251283770130.02.015.04621.010.254273966673875UNF:6:g9ZTGixdcDEXk/f7W5tl/g==MONTHUNF:6:BeK8RXOzZPqhIcaIQ1qEPQ==TCELLSUBUNF:6:3ax/QDOdOAKdYGfkkhtbag==CYTOKINEUNF:6:UbMENxN/B10WA2R2ZDYD7w==ANTIGENUNF:6:8JLFznMprNKBf/AfGklM2w==RESPONSE4621.00.4004970676151148.0.00.01.00.00.20060592945249905UNF:6:+/Lhdsz0lE4vhzREQ63h2A==PCTPOS_ADJ0.00196896904780656830.034747744276891720.10720093695330361.1.9130749605637170.04621.00.001UNF:6:nMxONQFgo1IBJkRB8wNg6A==PCTPOS_ADJ_UNITUNF:6:yOAEVN0UHM20feEUiBs3yg==NETWORKUNF:6:MAD3+UR2VdjDHRhoB6JrTg==UID953.0.28.0474.0821.0232.6306509447270.0698.2742616033769UNF:6:guUuWT6bnZdPwot7ZbGAwQ==MAB_NAMEUNF:6:aK9V2xfFX9t+7t5xmTx60Q==RX_CODEUNF:6:17T4dNvTPWbnJ4Mw0UkJMg==RX_LABELUNF:6:TUi3V4SE35iB4oHDG7TX9Q==VISITNO12.011.907172995780591474.00.78559387833624240.012.02.0.UNF:6:3tn5MSiYlbsIF24R1W4yiQ==MONTHUNF:6:4/mE9fhxQ2skEU2h/kbXHQ==DILUTION0.080.050.065.0.474.065.015.01584786495901UNF:6:NjptMWM7a5JNTZKgRcGH0w==INITIAL_DILUTION100.032.0881883538199100.081.96202531645567.25.00.0474.0UNF:6:hNThvHPtXXoa/KgG3i5g+g==CELLTYPEUNF:6:byZo1DgYWCz4BGfPQ8V5+g==HOSTCELLUNF:6:GXDYLP53pMy0liebOllnZA==ISOLATEUNF:6:weJ/P/y+LoHfzf2tPB+F/w==TITER_NUM42.083480649487441.6E-40.066.60452394643461100.0474.0100.0.UNF:6:l8jiDWLNSZ5s0PnJMF/h1g==RESPONSE474.00.210970464135021190.408428519281617440.0.1.00.00.0UNF:6:jhtBdzmLwwsTc1biwOVWhg==TITER_UNITUNF:6:YDG0/CJzz+/ECxPsaatfaA==NETWORKUNF:6:+0f1Qzi2KB8IdEd1mOV0Ew==PROTOCOL302.0.302.0302.00.0302.02244.00.0UNF:6:vI3P9/g5Fa7rzqFYFDfv5A==UID453.16310160428543461.0953.00.02244.0.264.7042902171979.0UNF:6:2nLR/0Q45eQrKF8wLT7X1w==RX_CODEUNF:6:W2uUpSgNQ/skBxGXITkDCg==RX_LABELUNF:6:IJG4RNXyCrZea30zrFkojA==VISITNO12.02244.00.02.04.409323136055831.8.7237076648841215.0UNF:6:hAyW1qKzJzSWWbQla6CALg==MONTHUNF:6:SEdTtbY36SW3qWZwn7+Skw==DILUTION0.050.02244.0.65.080.065.015.003343363465124UNF:6:dDzuijLjSTTXSTVh7kCJbg==CELLTYPEUNF:6:Do71kxvXxwZ2Bmyc+S5P7g==HOSTCELLUNF:6:qKpqi4EL++LBtTtsHEI7PQ==ISOLATEUNF:6:jNZKc2Ioi/KiEL7gvsJwPA==TITER_NUM0.028.969398021390342244.0.5.01183.9125.091.69903359274689UNF:6:tZCdIw981yzE8iWTWqxubA==RESPONSE0.00.00.433878499722093472244.01.00.0.0.2513368983957222UNF:6:zyiaWtYXAWbac68vZHvM5Q==TITER_UNITUNF:6:c8rmqRtnckDq9luXjROGzA==v302_immuno_data_dictionary.xlsxData dictionary application/vnd.openxmlformats-officedocument.spreadsheetml.sheet